Compare Raymond James Financial, Inc. (RJF) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs TG Therapeutics Inc — how do they compare? Raymond James Financial, Inc. trades at $167.8 (market cap $32.73B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: Raymond James Financial, Inc. is far larger — about 4× TG Therapeutics Inc's market cap, and Raymond James Financial, Inc. pays a 1.29% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RJF | TGTX | |
|---|---|---|
Market Cap | $32.73B | $8.26B |
Sector | Financials | Health |
52-Week High | $176.43 | $59.06 |
52-Week Low | $140.89 | $26.39 |
Dividend Yield | 1.29% | — |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $167.93, down 0.26% on the day, with a bullish technical outlook and consistent earnings beats in recent quarters. The stock shows strong fundamental performance with 2025 revenue of $13.84B and net income of $2.14B, supported by a P/E of 15.89. Analyst consensus is positive with a $176.83 price target, and recent news highlights advisor recruitment driving growth.
The outlook for RJF remains favorable due to earnings momentum and institutional interest, though risks include expense pressures and market volatility. The stock presents a growth opportunity with solid valuation support, but investors should monitor cost management and macroeconomic factors that could impact financial services performance.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
